Yes and No: FDA Panel Votes Shyly in Favor of Mipomersen
Kynamro (mipomersen) for homozygous familial hypercholesterolemia (HoFH) overcame testimony about liver problems, cancer in mice, possible cardiac risk, troubling immune responses and significant trial dropout rates to win a vote recommending approval from an FDA advisory panel.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST